Abstract
Drugs that act through noradrenergic and serotonergic mechanisms have historically served as the mainstays of pharmacologic treatments for obesity. This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpro-panolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets.
Similar content being viewed by others
References
National Institutes of Health and National Heart, Lung and Blood Institute (1998). Obes. Res. 6, 51S-210S.
Bray, G. A. (1991). Ann. Intern. Med. 115, 152–153.
Bray, G. A. (1999). Ann. Intern. Med. 31, 1–3.
Weintraub, M., Sundaresan, P. R., Madan, M., Schuster, B., Balder, A., Lasagna, L., and Cox, C. (1992). Clin. Pharmacol. Ther. 51, 586–594.
Weintraub, M., Sundaresan, P. R., Schuster, B., Ginsberg, G., Madan, M., Balder, A., Stein, E. C., and Byrne, L. (1992). Clin. Pharmacol. Ther. 51, 595–601.
Weintraub, M., Sundaresan, P. R., Schuster, B., Moscucci, M., and Stein, E. C. (1992). Clin. Pharmacol. Ther. 51, 602–607.
Weintraub, M., Sundaresan, P. R., Schuster, B., Averbuch, M., Stein, E. C., Cox, C., and Byrne, L. (1992). Clin. Pharmacol. Ther. 51, 608–614.
Weintraub, M., Sundaresan, P. R., Schuster, B., Averbuch, M., Stein, E. C., and Byrne, L. (1992). Clin. Pharmacol. Ther. 51, 615–618.
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., and Schaff, H. V. (1997). N. Engl. J. Med. 337, 581–588.
American Home Products Unveils Fen-Phen Settlement Plan. Reuters Health. (1999).
Bray, G. A. and Greenway, F. L. (1999). Endocr. Rev. 20, 805–875.
Munro, J. F., MacCuish, A. C., Wilson, E. M., and Duncan, L. F. P. (1968). BMJ 1, 352–356.
Weintraub, M. (1985). Clin. Pharmacol. Ther. 5, 53–79.
Morgan, J. P. and Funderburk, F. R. (1992). Am. J. Clin. Nutr. 55, 206S-210S.
Astrup, A., Breum, L., Toubro, S., Hein, P., and Quaade, F. (1992). Int. J. Obes. Relat. Metab. Disord. 16, 169–277.
Connoley, J. P., Liu, Y. L., Frost, I., Reckless, I. P., Heal, D. J., and Stock, M. J. (1999). Br. J. Pharmacol. 126, 1487–1495.
Stock, M. J. (1997). Int. J. Obes. 21, S25-S29.
Rolls, B. J., Shide, D. J., Thorwart, M. L., and Ulbrecht, J. S. (1998). Obes. Res. 6, 1–11.
Chapelot, D., Marmonier, C., Thomas, F., and Hanotin, C. (2000). Physiol. Behav. 58, 299–308.
Halford, J. L. G., Heal, D. J., and Blundell, J. E. (1994). Appetite 23, 306–307.
Seagle, H. M., Bessessen, D. H., and Hill, J. O. (1998). Obes. Res. 6, 115–121.
Hansen, D. L., Toubro, S., Stock, M. J., Macdonald, I. A., and Astrup, A. (1998). Am. J. Clin. Nutr. 6, 1180–1186.
Hansen, D. L., Toubro, S., Stock, M. J., Macdonald, I. A., and Astrup, A. (1999). Int. J. Obes. Relat. Metab. Disord. 23, 1016–1024.
Walsh, K. M., Lean, E., and Lean, M. E. (1999). Int. J. Obes. Relat. Metab. Disord. 23, 1009–1015.
Weintraub, M., Rubio, A., Golik, A., Byrne, L., and Scheinbaum, M. L. (1991). Clin. Pharmacol. Ther. 50, 330–337.
Ryan, D. H., Kaiser, P., and Bray, G. A. (1995). Obes. Res. 3, 553–559.
Bray, G. A., Ryan, D. H., Gordon, D., Heidingsfelder, S., Cerise, F., and Wilson, K. (1996). Obes. Res. 4, 263–270.
Lean, M. E. (1997). Int. J. Obes. 21, S30-S36.
Hanotin, C., Thomas, F., Jones, S. P., Leutenegger, E., and Drouin, P. (1998). Int. J. Obes. Relat. Metab. Disord. 22, 32–38.
Bray, G. A., Blackburn, G. L., Ferguson, J. M., Greenway, F. L., Jain, A. K., Mendel, C. M., Mendels, J., Ryan, D. H., Schwartz, S. L., Scheinbaum, M. L., and Seaton, T. B. (1999). Obes. Res. 7, 189–198.
Apfelbaum, M., Vague, P., Ziegler, O., Hanotin, C., Thomas, F., and Leutenegger, E. (1999). Am. J. Med. 106, 179–184.
Cuellar, G. E., Ruiz, A. M., Monsalve, M. C., and Berber, A. (2000). Obes. Res. 8, 71–82.
Fanghanel, G., Cortinas, L., Sanchez-Reyes, L., and Berber, A. (2000). Int. J. Obes. Relat. Metab. Disord. 24, 144–150.
Bach, D. S., Rissanen, A. M., Mendel, C. M., Shepherd, G., Weinstein, S. P., Kelly, F., Seaton, T. B., Patel, B., Pekkarinen, T. A., and Armstrong, W. F. (1999). Obes. Res. 7, 363–369.
Schuh, L. M., Schustser, C. R., Hopper, J. A., and Mendel, C. M. (2000). Psychopharmacology 147, 339–346.
James, P., Astrup, A., Finer, N., Hilsted, J. Kopelman, P., Rossner, S., Saris, W., and Van Gaal, L. (1999). Obes. Res. 7(Suppl. 1), 50S.
Fujioka, K., Seaton, T. B., Rowe, E., Jelinek, C. A., Raskin, P., Lebovitz, H. E., Weinstein, S. P., and the Sibutramine/Diabetes Clinical Study Group. (2000). Diabetes, Obesity and Metabolism 2, 1–13.
McMahon, F. G., Fujioka, K., Singh, B. N., Mendel, C. M., Rowe, E., Rolston, K., Johnson, F., and Mooradian, A. D. (2000). Arch. Intern. Med. 160, 2185–2191.
Rissanen, T., Pekkarinen, T., Heinanen, T., Saltevo, J., and Taskinen, M. R. (1999). Obes. Res. 7(Suppl. 1), 93S.
Griffiths, J., Byrnes, A. E., and Frost, G. (1995). Int. J. Obes. 19(Suppl. 2), 41.
Khan, M. A., Herzog, C. A., St. Peter, J. V., Hartley, G. G., Madlon-Kay, R., Dick, C. D., Asinger, R. W., and Vessey, J. T. (1998). N. Engl. J. Med. 339, 713–718.
Weissman, N. J., Tighe, J. F., Gottdiener, J. S. and Gwynne, J. T. (1998). for the Sustained-Release Dexfenfluramine study Group. N. Engl. J. Med. 339, 725–732.
Jick, H., Vasilakis, C., Weinrauch, L. A., Meier, C. R., Jick, S. S., and Derby, L. E. (1998). N. Engl. J. Med. 339, 719–724.
Wadden, T. A., Berkowitz, R. I., Silvestry, F., Vogt, R. A., St. John Sutton, M. G., Stunkard, A. J., Foster, G. D., and Aber, J. L. (1998). Obes. Res. 6, 278–284.
Wee, C. C., Phillips, R. S., Aurigemma, G., Erban, S., Kriegel, G., Riley, M., and Douglas, P. S. (1998). Ann. Intern. Med. 129, 870–874.
Ryan, D. H., Bray, G. A., Helmcke, F., Sander, G., Volaufova, J., Greenway, F., Subramaniam, P., and Glancy, D. L. (1999). Obes. Res. 7, 313–322.
Connolly, H. M. and McGoon, M. D. (1999). Curr. Prob. Cardiol. 24, 751–792.
Cannistra, L. B. and Cannistra, A. J. (1998). N. Engl. J. Med. 339, 771.
Hensrud, D. D., Conolly, H. M., Grogan, M., Miller, P. A., and Jensen, M. D. (1999). Mayo Clin. Proc. 74, 1302–1304.
Ryan, D. H., Bray, G. A., Greenway, F. L., and Helmcke, F. (1999). Obes. Res. 7(Suppl. 1), 50S.
Weyer, C., Gautier, J. F., and Danforth, E. (1999). Diabetes Metab. 25, 11–21.
World Health Organization. (1998). Obesity-Preventing and Managing the Global Epidemic. Report of a WHO Consultancy on Obesity, Geneva, 3–5 June, 1997. WHO: Geneva.
Bray, G. A. (1998). Lancet 352, 160–161.
Colditz, G. A., and Coakley, E. (1997). Int. J. Sports Med. 18, S162-S170.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ryan, D.H. Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. Endocr 13, 193–199 (2000). https://doi.org/10.1385/ENDO:13:2:193
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:13:2:193